Ars Pharmaceuticals (SPRY): Orbimed Advisors LLC reduced its stake -952K shares
Orbimed Advisors LLC reduced its stake in Ars Pharmaceuticals, per its Q3 2024 13F.
- 8.29M
- Shares reported · -952K vs prior quarter
- 2.2%
- Disclosed portfolio weight
- $120M
- Reported value
- Holdings as of
- Sep 30, 2024
- Filed
- Nov 14, 2024
What stands out in this filing
- 9,240,887 shares in Q2 2024, 8,288,510 now (−10.3% in share count).
- Reported at $120M, 2.18% of the portfolio value in this 13F filing.
- No other tracked manager reported the same kind of change for Q3 2024.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 8, 2024Insider · 2 peopleInsiders: 4 sales (~$2.8M)
- Oct 15, 2024Insider · 2 peopleInsiders: 6 sales (~$3.0M)
- Oct 16, 2024InsiderCFO sold ~$200K of SPRY shares in the open market
- Nov 11, 2024Insider · 1 personInsiders: 4 sales (~$9.5M)
- Nov 12, 2024Insider · 3 peopleInsiders: 12 sales (~$4.0M)
What came next
- Nov 19, 2024Insider · 2 peopleInsiders: 4 sales (~$2.8M)
- Nov 25, 2024InsiderOfficer sold ~$459K of SPRY shares in the open market
- Nov 26, 2024InsiderOfficer sold ~$593K of SPRY shares in the open market
- Nov 27, 2024InsiderOfficer sold ~$360K of SPRY shares in the open market
- Dec 2, 2024Insider · 3 peopleInsiders: 4 sales (~$2.0M)
- Dec 3, 2024Insider · 2 peopleInsiders: 2 sales (~$1.8M)
- Dec 4, 2024Insider · 3 peopleInsiders: 3 sales (~$919K)
- Dec 5, 2024InsiderOfficer sold ~$702K of SPRY shares in the open market
- Dec 6, 2024InsiderOfficer sold ~$712K of SPRY shares in the open market
- Dec 10, 2024Insider · 3 peopleInsiders: 5 sales (~$3.3M)
- Dec 11, 2024InsiderOfficer sold ~$186K of SPRY shares in the open market
- Dec 12, 2024Insider · 2 peopleInsiders: 2 sales (~$1.7M)
- Dec 13, 2024InsiderOfficer sold ~$329K of SPRY shares in the open market
- Dec 17, 2024Insider · 2 peopleInsiders: 4 sales (~$2.3M)
- Jan 6, 2025InsiderDirector sold ~$555K of SPRY shares in the open market
- Feb 3, 2025InsiderDirector sold ~$616K of SPRY shares in the open market
- Mar 5, 2025InsiderDirector sold ~$4.4K of SPRY shares in the open market
- Mar 6, 2025InsiderDirector sold ~$556K of SPRY shares in the open market
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Ars Pharmaceuticals
For Ars Pharmaceuticals, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SPRY page.
How this filing works
Explore the data
Common questions
What does this filing report about Ars Pharmaceuticals (SPRY) stock?
Orbimed Advisors LLC reduced its stake in Ars Pharmaceuticals, per its Q3 2024 13F. Now 8.29M shares, $120M reported value, 2.2% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Sep 30, 2024. Filed: Nov 14, 2024.
What stands out in this filing?
9,240,887 shares in Q2 2024, 8,288,510 now (−10.3% in share count). Reported at $120M, 2.18% of the portfolio value in this 13F filing. No other tracked manager reported the same kind of change for Q3 2024.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Ars Pharmaceuticals recently?
For Ars Pharmaceuticals, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the SPRY page.
Does this mean SPRY stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Ars Pharmaceuticals
- SEC Form 144Nov 9, 2026
- SEC Form 144Oct 30, 2026
- SEC Form 144Oct 19, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRMay 15, 2026
- SEC Form 13F-HRMay 15, 2026
Everything OQRO holds on this company is on its SPRY page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
